Back to search

Peptide record

TPDB25704

Antibacterial Antiviral Toxicity modified_plain modified
42 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB25704
Antibacterial Antiviral Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia
modified_plain
Yes
A 42-aa modified multi-activity (Antibacterial, Antiviral, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Modified, details unspecified
Sequence
SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGX
Physicochemical Analysis
C197H326N48O68S1
RCHFPW
L
4487.10
3.92
2
5
17
-3
6.52
0.045
118.33
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
2980
66.41
16
Residue Composition
number
1
A
0
R
2
N
2
D
0
C
3
E
3
Q
3
G
0
H
2
I
9
L
2
K
1
M
0
F
0
P
5
S
4
T
0
W
2
Y
2
V
Amino Acid Distribution
A: 1 R: 0 N: 2 D: 2 C: 0 E: 3 Q: 3 G: 3 H: 0 I: 2 L: 9 K: 2 M: 1 F: 0 P: 0 S: 5 T: 4 W: 0 Y: 2 V: 2
Chemical Descriptors
42
C197H326N48O68S1
4487.10
3.92
-3
6.52
0.045
Evidence Records 2 records
Evidence 1 Activity

Activity

<10% Cytotoxicity
Toxicity
10 µM
Cytotoxic
<10% Cytotoxicity | 10 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | MBio | 2020
Evidence 2 Activity

Activity

12% Cytotoxicity
Toxicity
10 µM
Cytotoxic
12% Cytotoxicity | 10 | µM | target cell: Vero E6 cells

Target

Vero E6 cells

Source & Reference

NA
DBAASP
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | MBio | 2020